go-v.orgdoi

Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo

Ayse Hande Nayman, Halime Ilhan Siginc, Ebru Itır Zemheri, Faruk Yencilek, Asif Yildirim, Dilek Telci · Journal of Cancer · 2019

  • DOI 10.7150/jca.29192
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2019

Abstract

Renal cell carcinoma (RCC) is the predominant type of kidney cancer.Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients.The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug.Elevated level of anti-apoptotic Bcl-2 protein is proposed to be an emerging feedback loop for the acquired drug-resistance in various cancer types.In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines.Everolimus and ABT-737 combination synergistically led to a decrease in the proliferation of primary site A-498 and metastatic site Caki-1 RCC cell lines, which was accompanied by a reduction in protein levels of cell cycle and mTOR pathway proteins.In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels.In order to confirm our in vitro findings, we have generated everolimus-resistant RenCa cell line (RenCa res ) to establish a RCC mouse xenograft model.Animals co-treated with everolimus and ABT-737 exhibited a complete suppression of tumor growth without any notable toxicity.This study thus proposes the everolimus-ABT-737 combination as a novel therapeutic strategy for the treatment of RCC to overcome the current clinical problem of everolimus resistance.

Open the resolved locator · 10.7150/jca.29192

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:15 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v10p1466.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.